Myramistin
Based on 1 Customer Validation
Myramistin (Miramistin) is a cationic surfactant and disinfectant preservative. Myramistin exhibits high bactericidal activity against Staphylococcus aureus and Escherichia coli, shows lower activity against yeasts and fungi, and is active against HIV, measles virus, mumps virus, as well as influenza viruses of the H3N2 and H5N1 subtypes. Myramistin adsorbs to the negatively charged microbial cell membrane, leading to increased membrane permeability and disruption of membrane integrity, which ultimately results in leakage of intracellular contents, enzyme inactivation, and the death of bacteria/fungi/enveloped viruses.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.32%
- CAS No.: 15809-19-5
- 화학식: C26H47ClN2O
- 분자량:439.12
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Fibroblast | CC50 |
7.21 μg/mL
Compound: Miramistin
|
Cytotoxicity against human skin fibroblasts assessed as cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human skin fibroblasts assessed as cell viability measured after 72 hrs by MTT assay
|
[PMID: 33385851] |
| HEK293 | CC50 |
6.08 μg/mL
Compound: Miramistin
|
Cytotoxicity against human HEK293 cells assessed as cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human HEK293 cells assessed as cell viability measured after 72 hrs by MTT assay
|
[PMID: 33385851] |
| HSF (VGS) | CC50 |
9.4 μg/mL
Compound: Miramistin
|
Cytotoxicity against human HSF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human HSF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 33310546] |
Myramistin (30-50 μg/mL) exhibits dose-dependent anti-HIV activity in MT-4 cells, and inhibits HIV p24 production in Jurkat-tat cells when added simultaneously with HIV-1[1].
Myramistin (10-20 μg/mL; 17-24 h) inhibits the growth of Staphylococcus aureus FDA 209P, Staphylococcus aureus INA 00761, and Bacillus mesentericus VKPM B-4177, with MIC values of 20, 10, and 10 μg/mL, respectively[2].
Myramistin (5-10 μg/mL; 17-24 h) inhibits the growth of Staphylococcus aureus FDA 209P, with an MIC of 5 μg/mL[2].
Myramistin (0.005-0.05%) potently inhibits the replication of measles virus strain Edmonson and mumps virus strain PetroNov/03 in Vero cell cultures, with optimal prophylactic concentrations of 0.05% and 0.005%, respectively[3].
Myramistin (0.5-1000 μg/mL; 24 h) potently inhibits and kills Staphylococcus aureus (ATCC 209p), with an MIC of 8 μg/mL and an MBC of 16 μg/mL; it also inhibits and kills Escherichia coli (CDC F-50), with an MIC of 32 μg/mL and an MBC of 128 μg/mL[4].
After a 1-minute exposure in suspension, Myramistin (0.1-0.2%; 1-15 min) produces a log10 reduction factor of ≥ 6.00 against Staphylococcus aureus (ATCC 209p) and a log10 reduction factor of ≥ 4.56 against Escherichia coli (CDC F-50); a 15-minute exposure completely inhibits the growth of both strains[4].
Myramistin (0.1-0.2%; 1-15 min) reduces the log10 reduction coefficient of Staphylococcus aureus (ATCC 209p) on metal surfaces by ≥ 3.20 and that of Escherichia coli (CDC F-50) by ≥ 3.41 after 1 minute of exposure; its activity is reduced by 1-3 log10 units compared with that in suspension tests[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (male, 200-230 g, experimentally induced bacterial skin infection)[4]
-
Dosage:0.2%
-
Administration:topical; single exposure; 5 minutes
-
Result:Reduced the number of viable E. coli cells by approximately 2.6 log10 units.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 15809-19-5
-
Appearance Solid
-
분자량 439.12
-
화학식 C26H47ClN2O
-
Color Light yellow to yellow
-
SMILES
CCCCCCCCCCCCCC(NCCC[N+](C)(C)CC1=CC=CC=C1)=O.[Cl-]
-
Synonyms
Miramistin
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
용액&용해도
DMSO : 100 mg/mL (227.73 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
순도&문서
-
Data Sheet (269 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kryvorutchenko IuL, et al. Antiseptic myramistin possesses the strong anti-HIV properties. Mikrobiolohichnyi zhurnal (Kiev, Ukraine : 1993). 1996;58(5):90-2. [Content Brief]
[2]. Vertelov GK, et al. A versatile synthesis of highly bactericidal Myramistin® stabilized silver nanoparticles. Nanotechnology. 2008 Sep 03;19(35):355707. [Content Brief]
[3].
Agafonov AP, et al. In vitro study of antiviral activity of Myramistin against measles and mumps viruses. Antibiot Khimioter. 2005;50(5-6):17-9. Russian.
[Content Brief]
[4]. Agafonova MN, et al. Antibacterial activity profile of miramistin in in vitro and in vivo models. Microbial pathogenesis. 2020 May;142:104072. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2773 mL | 11.3864 mL | 22.7728 mL | 56.9320 mL |
| 5 mM | 0.4555 mL | 2.2773 mL | 4.5546 mL | 11.3864 mL | |
| 10 mM | 0.2277 mL | 1.1386 mL | 2.2773 mL | 5.6932 mL | |
| 15 mM | 0.1518 mL | 0.7591 mL | 1.5182 mL | 3.7955 mL | |
| 20 mM | 0.1139 mL | 0.5693 mL | 1.1386 mL | 2.8466 mL | |
| 25 mM | 0.0911 mL | 0.4555 mL | 0.9109 mL | 2.2773 mL | |
| 30 mM | 0.0759 mL | 0.3795 mL | 0.7591 mL | 1.8977 mL | |
| 40 mM | 0.0569 mL | 0.2847 mL | 0.5693 mL | 1.4233 mL | |
| 50 mM | 0.0455 mL | 0.2277 mL | 0.4555 mL | 1.1386 mL | |
| 60 mM | 0.0380 mL | 0.1898 mL | 0.3795 mL | 0.9489 mL | |
| 80 mM | 0.0285 mL | 0.1423 mL | 0.2847 mL | 0.7117 mL | |
| 100 mM | 0.0228 mL | 0.1139 mL | 0.2277 mL | 0.5693 mL |
Myramistin Related Classifications
HY-103658 Related Classifications
Powered by Bioz